PAMELA GARZA: Open Payments
NPI 1841232758 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$811 in 30 payments from 15 companies in 2025. Trend: 2023 $333 · 2024 $344 · 2025 $811
Food & beverage: $811
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $182 |
| E.R. Squibb & Sons, L.L.C. | 1 | $120 |
| Daiichi Sankyo Inc. | 4 | $77 |
| AstraZeneca Pharmaceuticals LP | 3 | $61 |
| Genmab U.S., Inc. | 2 | $58 |
| Celgene Corporation | 3 | $55 |
| KYOWA KIRIN, INC. | 2 | $50 |
| GlaxoSmithKline, LLC. | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Gilead Sciences, Inc. | 1 | $31 |
Products named: RYBREVANT, BREYANZI, LYNPARZA, Enhertu, Epkinly, REBLOZYL, POTELIGEO, TECVAYLI.
Industry payments across TX — which companies pay providers there.
